Abstract
Estrogen deficiency in post-menopausal osteoporosis not only causes decreased bone mass in mandibular bone, but also affect cartilaginous ossification in mandibular condyle. Although the mechanisms of action are not entirely clear, estrogen is thought to promote the programmed cell death of osteoclasts and hence reduce their period of activity. Treatment with estrogen or some agents prevent bone loss in alveolar bone through blocking production of cytokines in osteoblasts and promoting osteoclast apoptosis. It's necessary to address basic principles and current concepts in bone remodeling, mediators of bone resorption and their clinical relevance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
